Your browser doesn't support javascript.
loading
The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19
Toçoglu, Aysel; Dheir, Hamad; Demirci, Taner; Kurt, Rumeysa; Salihi, Salih; Yaylaci, Selçuk; Çakar, Gözde Çakırsoy; Toptan, Hande; Karabay, Oguz; Sipahi, Savas.
  • Toçoglu, Aysel; Sakarya University Faculty of Medicine. Department of Internal Medicine. Sakarya. TR
  • Dheir, Hamad; Sakarya University Faculty of Medicine. Division of Nephrology. Sakarya. TR
  • Demirci, Taner; Sakarya University Faculty of Medicine. Division of Endocrinology. Sakarya. TR
  • Kurt, Rumeysa; Sakarya University Faculty of Medicine. Department of Internal Medicine. Sakarya. TR
  • Salihi, Salih; Sakarya University Faculty of Medicine. Department of Cardiovascular Surgery. Sakarya. TR
  • Yaylaci, Selçuk; Sakarya University Faculty of Medicine. Department of Internal Medicine. Sakarya. TR
  • Çakar, Gözde Çakırsoy; Sakarya University Faculty of Medicine. Department of Clinic Pathology. Sakarya. TR
  • Toptan, Hande; Sakarya University Faculty of Medicine. Department of Microbiology. Sakarya. TR
  • Karabay, Oguz; Sakarya University Faculty of Medicine. Department of Infection Diseases and Microbiology. Sakarya. TR
  • Sipahi, Savas; Sakarya University Faculty of Medicine. Division of Nephrology. Sakarya. TR
Rev. Assoc. Med. Bras. (1992) ; 67(9): 1299-1304, Sept. 2021. tab, graf
Article in English | LILACS | ID: biblio-1351491
ABSTRACT
SUMMARY

OBJECTIVE:

This study aimed to investigate the effectiveness of dexamethasone in dialysis patients with COVID-19 and whether it predicts mortality.

METHODS:

This is a comparative cross-sectional study of 113 consecutive patients with COVID-19 with severe pneumonia signs. The patients were divided into two groups according to the use of dexamethasone treatment group 1 (n=45) included patients who were treated with dexamethasone and group 2 (n=68) who did not receive dexamethasone.

RESULTS:

The mean age of both groups was 67.0±10.6 and 67.2±13.0 years, respectively (p=0.947). With respect to demographic and laboratory findings, there were no significant differences between the two groups (p>0.05). The hospitalization time of patients in group 1 was longer than that in group 2 (11 [7-17] days vs. 8 [5.3-14] days, p=0.093]. The 28-day survival rate was 54.2% in the group receiving dexamethasone treatment and 79.5% in the group not receiving dexamethasone treatment (p=0.440).

CONCLUSION:

Dexamethasone did not reduce mortality rates and the requirement for intensive care unit in dialysis patients with COVID-19. Larger prospective randomized clinical trials are required to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: COVID-19 Type of study: Controlled clinical trial / Observational study / Prevalence study / Prognostic study / Risk factors Limits: Aged / Humans Language: English Journal: Rev. Assoc. Med. Bras. (1992) Year: 2021 Type: Article Affiliation country: Turkey Institution/Affiliation country: Sakarya University Faculty of Medicine/TR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: COVID-19 Type of study: Controlled clinical trial / Observational study / Prevalence study / Prognostic study / Risk factors Limits: Aged / Humans Language: English Journal: Rev. Assoc. Med. Bras. (1992) Year: 2021 Type: Article Affiliation country: Turkey Institution/Affiliation country: Sakarya University Faculty of Medicine/TR